美国亚利桑那大学Deepta Bhattacharya、Janko Nikolich-ugich等研究人员合作发现，正交SARS-CoV-2血清学检测可监测低患病率社区并揭示持久的体液免疫。相关论文于2020年10月13日在线发表在《免疫》杂志上。

Title: Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low Prevalence Communities and Reveal Durable Humoral Immunity.

Author: Tyler J. Ripperger, Jennifer L. Uhrlaub, Makiko Watanabe, Rachel Wong, Yvonne Castaneda, Hannah A. Pizzato, Mallory R. Thompson, Christine Bradshaw, Craig C. Weinkauf, Christian Bime, Heidi L. Erickson, Kenneth Knox, Billie Bixby, Sairam Parthasarathy, Sachin Chaudhary, Bhupinder Natt, Elaine Cristan, Tammer El Aini, Franz Rischard, Janet Campion, Madhav Chopra, Michael Insel, Afshin Sam, James L. Knepler, Andrew P. Capaldi, Catherine M. Spier, Michael D. Dake, Taylor Edwards, Matthew E. Kaplan, Serena Jain Scott, Cameron Hypes, Jarrod Mosier, David T. Harris, Bonnie J. LaFleur, Ryan Sprissler, Janko Nikolich-ugich, Deepta Bhattacharya

Issue&Volume: 2020-10-13

Abstract: We conducted a serological study to define correlates of immunity against SARS-CoV-2. Relative to mild COVID-19 cases, individuals with severe disease exhibited elevated virus-neutralizing titers and antibodies against nucleocapsid (N) and the receptor binding domain (RBD) of spike protein. Age and sex played lesser roles. All cases, including asymptomatic individuals, seroconverted by 2 weeks post-PCR confirmation. Spike RBD and S2 and neutralizing antibodies remained detectable through 5-7 months post-onset, whereas α-N titers diminished. Testing of 5882 members of the local community revealed only 1 sample with seroreactivity to both RBD and S2 that lacked neutralizing antibodies. This fidelity could not be achieved with either RBD or S2 alone. Thus, inclusion of multiple independent assays improved the accuracy of antibody tests in low seroprevalence communities and revealed differences in antibody kinetics depending on the antigen. We conclude that neutralizing antibodies are stably produced for at least 5-7 months after SARS-CoV-2 infection.

DOI: 10.1016/j.immuni.2020.10.004

Source: https://www.cell.com/immunity/fulltext/S1074-7613(20)30445-3